Compare Biogen Inc (BIIB) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Kinder Morgan Inc — how do they compare? Biogen Inc trades at $206.54 (market cap $30.13B), while Kinder Morgan Inc trades at $31.69 (market cap $70.10B). The key difference: Kinder Morgan Inc is far larger — about 2.3× Biogen Inc's market cap, and Kinder Morgan Inc pays a 3.75% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | KMI | |
|---|---|---|
Market Cap | $30.13B | $70.10B |
Sector | Health | Energy |
52-Week High | $216.63 | $34.31 |
52-Week Low | $128.93 | $25.84 |
Enterprise Value | $37.20B | $102.15B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
KMI trades at $31.76, up 1.16% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates, and raised full-year guidance. Revenue grew to $16.94B in 2025, with net income margin expanding to 19.31%. Recent news highlights a $5 billion Western Gateway Pipeline joint venture final investment decision.
Outlook is supported by robust cash flow, a $10 billion project backlog, and growing LNG demand, but risks include high debt levels and execution challenges. Analysts are mixed with 47% buy ratings. The stock offers a dividend yield near 3.7%, appealing for income-focused investors amid stable fee-based operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
